MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Checkpoint Therapeutics Inc

Fermé

SecteurSoins de santé

4.04 0.25

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.02

Max

4.04

Chiffres clés

By Trading Economics

Employés

23

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+31.19% upside

Dividendes

By Dow Jones

Prochains Résultats

9 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

207M

Ouverture précédente

3.79

Clôture précédente

4.04

Sentiment de l'Actualité

By Acuity

50%

50%

180 / 386 Classement par Healthcare

Checkpoint Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 mars 2025, 10:23 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma

14 déc. 2024, 00:24 UTC

Principaux Mouvements du Marché

Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval

25 juil. 2024, 13:02 UTC

Principaux Mouvements du Marché

Checkpoint Therapeutics Shares Rise After FDA Accepts Resubmission of Cosibelimab

10 mars 2025, 02:12 UTC

Acquisitions, Fusions, Rachats

Checkpoint Controlling Shareholder Fortress Has Agreed to Vote in Favor of Transaction >524715.BY

10 mars 2025, 02:12 UTC

Acquisitions, Fusions, Rachats

Sun Pharma, Checkpoint Transaction Expected to Complete in 2Q 2025 >524715.BY

10 mars 2025, 02:11 UTC

Acquisitions, Fusions, Rachats

Sun Pharma, Checkpoint, Fortress Biotech Enter Into Royalty Agreement >524715.BY

10 mars 2025, 02:11 UTC

Acquisitions, Fusions, Rachats

Checkpoint Shareholders Entitled to Receive Up to Additional $0.70 if Cosibelimab if Approved in EU Prior to Certain Deadlines >524715.BY

10 mars 2025, 02:10 UTC

Acquisitions, Fusions, Rachats

Checkpoint Shareholders to Receive Upfront Cash Payment of $4.10/Share, Contingent Value Right >524715.BY

10 mars 2025, 02:10 UTC

Acquisitions, Fusions, Rachats

Sun Pharma to Acquire Checkpoint Therapeutics >524715.BY CKPT

10 mars 2025, 02:06 UTC

Acquisitions, Fusions, Rachats

Sun Pharma To Acquire Checkpoint Therapeutics >524715.BY CKPT

Comparaison

Variation de prix

Checkpoint Therapeutics Inc prévision

Objectif de Prix

By TipRanks

31.19% hausse

Prévisions sur 12 Mois

Moyen 5.3 USD  31.19%

Haut 7 USD

Bas 4.1 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

1

Achat

2

Maintien

0

Vente

Sentiment

By Acuity

180 / 386Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

$

À Propos Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.